Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

GlaxoSmithKline plc (GSK): The Perfect Tonic for Troubled Markets

GlaxoSmithKline plc (ADR) (NYSE:GSK)LONDON — If you can keep your head while everyone around is losing theirs, you probably hold shares in GlaxoSmithKline plc (LON:GSK). Last week’s market mayhem won’t have troubled this pharmaceutical giant’s loyal army of long-term investors — you don’t measure an investment like Glaxo in days, but years and years.

GlaxoSmithKline plc (LON:GSK) is just the tonic in troubled times. As markets fret over Japan’s last throw of the monetary dice and the Federal Reserve’s plans to unwind QE, defensive investors will be pondering their options. Cash remains on the sick list. Gold bugs have been stung. Bond investors fear a bubble. Defensive FTSE 100 blue chips such as Glaxo shine by comparison.

You can get 2.5% on cash right now, but only if you lock your money away for five years with a bank you’ve never heard of. If you want easy access, you’ll barely get 1.5%. Right now, GlaxoSmithKline plc (LON:GSK) yields a far healthier 4.2%, with any share price growth on top. Better still, management hiked the dividend 6% to 18 pence in the first quarter: No savings account has such a progressive attitude to its customers. Share-price performance has been solid rather than spectacular. GlaxoSmithKline plc (LON:GSK) is up 24% over one year, against 27% for the FTSE 100, but nobody buys this stock to gorge themselves on growth. You invest to line your portfolio’s stomach and for those juicy dividends. Yet Glaxo has still risen a tasty 52% over the last three years, against 33% for the index

Glaxo aids recovery
Glaxo does have some problems. Sales and earnings have dipped slightly, and the global government spending squeeze won’t help. It is under investigation by the OFT for allegedly abusing its dominant market position over antidepressant treatment Seroxat, a charge that GlaxoSmithKline plc (LON:GSK) denies. But it has a healthy drugs pipeline and cash flow, and its plans to offload iconic brands Lucozade and Ribena could generate yet more cash to reinvest in the business or fund further share repurchases. Glaxo is already repurchasing between 1 billion pounds and 2 billion pounds of its shares. Earnings per share growth should be around 3% to 4% — decent, but hardly daredevil. That’s good enough for me right now.

Glaxo looks perfectly valued at 15.5 times earnings. That’s a little too perfect for my liking. If the bond market boos Japan offstage or Bernanke fluffs his QE exit lines, GlaxoSmithKline plc (LON:GSK) could become that little bit cheaper, while its yield would be even more generous. Now that would be a real tonic.

The article GlaxoSmithKline: The Perfect Tonic for Troubled Markets originally appeared on Fool.com and is written by Harvey Jones.

Harvey Jones owns shares of GlaxoSmithKline. The Motley Fool recommends GlaxoSmithKline.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Loading Comments...